Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
March 02 2020 - 7:00AM
Recro, Inc. (NASDAQ:REPH) a leading contract development and
manufacturing organization (CDMO) with integrated solutions for the
development, formulation, regulatory support, manufacturing and
packaging of oral solid dose drug products, today announced that it
will report year end 2019 financial results on Wednesday, March 4,
2020. Recro's management team will host a conference call and audio
webcast at 8:00 a.m. ET on Wednesday, March 4, 2020 to discuss the
financial results and recent operational highlights.
To access the conference call, please dial (844)
243-4691 (local) or (225) 283-0379 (international) at least 10
minutes prior to the start time and refer to conference ID 4297426.
A live audio webcast of the call will be available under "Events"
in the Investor section of the Company's website,
https://ir.recropharma.com/events. An archived webcast will be
available on the Company's website approximately two hours after
the event and will be available for 30 days.
About Recro, Inc.
Recro is a revenue-generating contract
development and manufacturing, or CDMO, business, located in
Gainesville, GA. The Company leverages its formulation and
development expertise to develop and manufacture pharmaceutical
products using proprietary delivery technologies and know-how for
commercial and development-stage partners who commercialize or plan
to commercialize these products. These collaborations result in
revenue streams including manufacturing fees, royalties, profit
sharing and research and development fees, which support continued
operations. For more information please visit
www.recrogainesville.com.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Recro's expectations about its
future performance and opportunities that involve substantial risks
and uncertainties. When used herein, the words "anticipate,"
"believe," "estimate," “expect”, “intend”, "may," "plan,"
“predict”, “project”, “will”, “would”, “could”, “should”,
“potential”, “seek”, “evaluate”, “pursue”, “continue”, “design”,
“impact”, “affect”, “forecast”, "target", ”outlook”, “initiative”,
“objective”, “designed”, “priorities”, “goal” or the negative of
such terms and similar expressions, as they relate to Recro or its
management, are intended to identify forward-looking statements
although not all forward-looking statements contain these
identifying words. Such statements are based on assumptions and
expectations that may not be realized and are inherently subject to
risks, uncertainties and other factors, many of which cannot be
predicted with accuracy and some of which might not seen be
anticipated. Recro assumes no obligation to update any such
forward-looking statements. Factors that could cause Recro’s actual
performance to materially differ from those expressed in the
forward-looking statements set forth in this press release include,
without limitation, the risks and uncertainties included in Recro’s
filings with the Securities and Exchange Commission at
www.sec.gov.
CONTACT:
Investor Relations Contact: Argot Partners Sam Martin / Claudia
Styslinger (212) 600-1902 sam@argotpartners.com
claudia@argotpartners.com
Recro, Inc. Ryan D. Lake (484) 395-2436
rlake@recropharma.com
Media Contact: Argot Partners David Rosen (212) 600-1902
david.rosen@argotpartners.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Oct 2023 to Oct 2024